Stock·NASDAQ·Industrials
Verisk Analytics, Inc. (VRSK)
- Market cap
- $24.54B
- P/E
- 28.17
- Dividend yield
- 1.04%
- Street target
- $228.00median of 19 analysts
- 52-week range
- $155.94 $239.47
The short version
Where VRSK stands today, in four lines, and what CleaRank Financial AI makes of it.
VRSK at a glance
Verisk Analytics, Inc. (VRSK): Buy, 70/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($179.46 and $187.82).
- Earnings VRSK beat estimates in 5 of its last 5 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $19.8M and bought $1.0M over the last 18 months.
- Valuation P/E of 28.2 against 34.0 for the Industrials sector: broadly in line with peers (-17%).
Figures as of October 16, 2026.
CleaRank Financial AI
Verisk Analytics (VRSK) is currently trading at $187.52, below its 200-day simple moving average of $187.82, indicating a near-term technical headwind.
However, the company has a strong analyst consensus with a 'Buy' rating and a median price target of $228, implying a 21.6% upside potential. The company's balance sheet presents a risk, as shareholder equity is negative, meaning liabilities exceed assets. This is noted as a balance-sheet risk rather than a sign of low debt. Despite this, the consistent positive earnings surprises, with the most recent available quarter beating estimates by 13.04%, suggest underlying business strength. The company's revenue growth of 4.4% is below the sector median of 11.7%, but forward estimates indicate a return to stronger growth in the coming years.
Only on CleaRank
Figures we compute ourselves from VRSK's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $187.52 is 4.5% above the 50-day simple moving average of $179.46.Price above its 200-day average ›
The price is 0.2% below the 200-day simple moving average of $187.82.50-day average above the 200-day ›
The 50-day average ($179.46) is 4.5% below the 200-day average ($187.82), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 38% of its 52-week range, between $155.94 and $239.47.
VRSK share price
Pick a period: each tab shows how far VRSK has moved over it, to the last close.
Today's trading
Where VRSK sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 28.17 is 17.1% below the Industrials median of 34.0.P/S below the sector median ›
The price-to-sales ratio of 7.83 is 95.7% above the sector median of 4.0.Profitable over the last 12 months ›
Net income over the last 12 months was $885.5M on revenue of $3.1B, a net margin of 28.2%.Beat estimates in most recent reports ›
VRSK beat the EPS estimate in 5 of its last 5 reports.Pays a dividend ›
The trailing dividend yield is 1.04%, or $1.95 a share a year.
Key statistics
The headline figures for VRSK.
As of October 16, 2026, VRSK trades at $187.52, with a market value of $24.54B, a P/E ratio of 28.17 and a dividend yield of 1.04%.
What the numbers say
CleaRank Financial AI's reading of VRSK's valuation, growth and risks.
Verisk Analytics (VRSK) trades at a P/E ratio of 28.17, which is below the sector average of 34, suggesting a potential valuation discount relative to its peers.
Its price-to-sales ratio of 7.83 is also higher than the sector average of 4.0, indicating a premium valuation on a revenue basis. Despite the strong profitability metrics, the company's balance sheet shows negative shareholder equity, which is a notable risk. While revenue growth of 4.4% is below the sector median of 11.7%, forward estimates project a return to stronger growth. The current valuation, while appearing reasonable on a P/E basis compared to the sector, warrants attention given the balance sheet concerns and the premium price-to-sales ratio.
VRSK against the Industrials sector
How VRSK compares with the median Industrials stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (-17% difference), suggesting fair market pricing relative to industry standards.
Return vs XLI: Since May 5, 2025, VRSK has lost 36.4% against a gain of 24.7% for XLI.
Performance against XLI
VRSK and the Industrials sector fund over the same days.
Revenue and earnings
How much VRSK sells, and how much of it becomes profit.
Revenue growth: Revenue grew 6.6% in FY2025 to $3.1B, from $2.9B a year earlier.
Profit margin: The net margin was 29.6% in FY2025, down from 33.2% the year before.
Profitable: VRSK earned $908M in FY2025.
Earnings reality check
Did VRSK beat what analysts expected, and how did the stock react?
Earnings record: VRSK beat the analyst estimate in 5 of the last 5 quarters.
Market reaction: The stock fell in the first session after 2 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Feb 18, 2026after close | $1.61 | $1.82 | +13.04% | -0.10% | +6.38% |
| Oct 29, 2025after close | $1.70 | $1.72 | +1.18% | +4.62% | +2.91% |
| Jul 30, 2025after close | $1.77 | $1.88 | +6.21% | +1.18% | -3.81% |
| May 7, 2025after close | $1.68 | $1.73 | +2.98% | -0.66% | -2.78% |
| Feb 26, 2025after close | $1.60 | $1.61 | +0.63% | +0.72% | +3.08% |
Reports after February 18, 2026 are not yet in our data.
As of October 16, 2026, VRSK has beaten the analyst EPS estimate in 5 of its last 5 reported quarters and fell in the first trading session after 2 of those beats; its most recent report in our data, on February 18, 2026, came in 13.04% above the estimate and the stock moved -0.10% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 65.3, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 65.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of VRSK
The score, the reasoning behind it, and what could move the price next.
Verisk Analytics (VRSK) is currently trading above its 50-day SMA of $179.46 and its 20-day EMA of $176.43, suggesting some underlying support in the shorter term.
However, the price is just below its 200-day SMA of $187.82, indicating a potential resistance level and a lack of a clear long-term trend. The 14-day RSI is at 65.27, signaling bullish momentum without being overbought. The MACD is at 1.07, also indicating bullish momentum. The CCI is at 143.52, further supporting a bullish technical outlook. Given the price's proximity to the 200-day SMA, a break above this level could signal a continuation of an upward trend, while a failure to do so might lead to a pullback towards the 50-day SMA.
Consistent EPS Beats ›
Verisk Analytics has a strong track record of exceeding analyst EPS estimates, with the most recent available quarter showing a 13.04% surprise, indicating operational efficiency and reliable performance.
Source: Earnings ReportsPositive Analyst Sentiment and Price Targets ›
The median Wall Street price target of $228 suggests a 21.6% upside from the current price, with a 'Buy' consensus rating from 19 analysts.
Source: Wall Street Analysts
Negative Shareholder Equity ›
The company's balance sheet shows negative shareholder equity, a risk factor indicating liabilities exceed assets.
Source: Company FundamentalsModerate Insider Selling Signal ›
Insiders have sold $19.8 million worth of stock compared to $1 million in purchases, indicating a moderate sell signal that warrants monitoring.
Source: Insider Transactions
- The stock is trading just below its 200-day SMA, suggesting this level could act as resistance. A decisive move above $187.82 would be a bullish signal.
Technical indicators
Momentum and trend for VRSK, from its daily closes.
As of October 16, 2026, with VRSK at $187.52, its 14-day RSI is 65.3 (showing bullish momentum without being overbought), its 50-day simple moving average is $179.46 and its 200-day is $187.82.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What VRSK moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, VRSK's 1-year correlation of daily returns is +0.06 with S&P 500 (SPY), -0.04 with Nasdaq 100 (QQQ), +0.02 with Bitcoin (BTC) and -0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
11 of 19 analysts rate it a buy or strong buy, 8 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $228.00 is 21.6% above the price.More buy ratings than three months ago ›
11 of 19 rate it a buy now, against 10 of 19 three months ago.
VRSK Wall Street View
12-month price targets
The price, $187.52, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 13, 2026 | BMO Capital | Maintains | Outperform |
| Oct 13, 2026 | Morgan Stanley | Maintains | Equal-Weight |
| Sep 8, 2026 | Barclays | Maintains | Overweight |
| Jul 30, 2026 | UBS | Maintains | Neutral |
| Jul 30, 2026 | Evercore ISI Group | Maintains | In-Line |
| Jul 30, 2026 | Wells Fargo | Maintains | Overweight |
As of October 16, 2026, 19 Wall Street analysts cover VRSK: 11 rate it a buy or strong buy, 8 a hold and 0 a sell or strong sell. Their 12-month price targets range from $195.00 to $260.00, with a median of $228.00, 21.6% above the price of $187.52.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
VRSK trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from VRSK's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much VRSK tends to move, against the market and on its own.
The long record
VRSK's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.32% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 49.2%, from June 2025 to May 2026; the price is still 40.7% below that peak.Most 1-year holds ended higher ›
78% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $24,858, against $42,525 in the S&P 500 (SPY).
VRSK Drawdowns & Recovery
As of October 16, 2026, VRSK's worst peak-to-trough fall over the last 10 years with dividends reinvested was -49.2% (June 2025 to May 2026); it is still 40.7% below that peak, and 78% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into VRSK in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: VRSK trailed the S&P 500 over this period: $24,858 against $42,525.
A $10,000 investment in VRSK in October 2016 would be worth about $24,858 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to VRSK, and which have not.
Strongest month, July: an average of +6.07%, up in 9 of 10 years.
Weakest month, February: an average of -2.66%, up in 4 of 10 years.
This month, October: has averaged -2.45%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, VRSK's strongest calendar month has been July (average +6.07%, up in 9 of 10 years) and its weakest February (average -2.66%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in VRSK, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VRSK today could grow to about $20,363 by 2036 in the base case, with a 90th-percentile outcome near $55,907 and a 10th-percentile outcome around $7,417. The simulation models price only; at today's 1.04% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
VRSK Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $249 for VRSK by 2030 in the base case, from $188 today (1.3x over 4 years). The 10th-percentile path ends near $132. These are outcomes of a Monte Carlo simulation run on VRSK's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $146 | $201 | $277 | |
| 2028 | $138 | $216 | $340 | |
| 2029 | $133 | $232 | $404 | |
| 2030 | $132 | $249 | $472 | |
| 2031 | $131 | $268 | $547 |
Method: a lognormal simulation of VRSK's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
VRSK insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.0M on the open market and sold $19.8M.
As of October 16, 2026, VRSK insiders reported 33 open-market sales worth $19.8M and 7 open-market purchases worth $1.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Samuel G. Liss
Director
|
Grant | 156 | - |
| Sep 15, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $74.0K |
| Sep 1, 2026 | Lee M Shavel
Chief Executive Officer
|
Sell | 3.5K | $683.8K |
| Sep 1, 2026 | Lee M Shavel
Chief Executive Officer
|
Option | 3.5K | $367.6K |
| Aug 17, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $72.0K |
| Aug 3, 2026 | Lee M Shavel
Chief Executive Officer
|
Sell | 3.5K | $696.2K |
| Aug 3, 2026 | Lee M Shavel
Chief Executive Officer
|
Option | 3.5K | $367.6K |
| Jul 31, 2026 | Kathy Card Beckles
Officer
|
Sell | 2.0K | $394.9K |
| Jul 29, 2026 | Lee M Shavel
Chief Executive Officer
|
Sell | 2.5K | $550.0K |
| Jul 15, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $76.8K |
| Jun 30, 2026 | Gregory S. Hendrick
Director
|
Grant | 146 | - |
| Jun 30, 2026 | Samuel G. Liss
Director
|
Grant | 167 | - |
| Jun 30, 2026 | Pradip Patiath
Director
|
Grant | 69 | - |
| Jun 30, 2026 | Christopher John Perry
Director
|
Grant | 146 | - |
| Jun 30, 2026 | Sabra R Purtill
Director
|
Grant | 163 | - |
| Jun 15, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $71.8K |
| Jun 5, 2026 | Samuel G. Liss
Director
|
Sell | 4.7K | $851.1K |
| Jun 5, 2026 | Samuel G. Liss
Director
|
Option | 4.7K | $378.0K |
| Jun 2, 2026 | Samuel G. Liss
Director
|
Sell | 6.8K | $1.2M |
| Jun 2, 2026 | Samuel G. Liss
Director
|
Option | 6.8K | $547.5K |
| Jun 1, 2026 | Bruce Edward Hansen
Director
|
Sell | 2.3K | $408.8K |
| Jun 1, 2026 | Bruce Edward Hansen
Director
|
Option | 2.3K | $189.1K |
| May 22, 2026 | Bruce Edward Hansen
Director
|
Sell | 2.3K | $400.5K |
| May 22, 2026 | Bruce Edward Hansen
Director
|
Option | 2.3K | $189.0K |
| May 19, 2026 | Jeffrey J Dailey
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Bruce Edward Hansen
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Gregory S. Hendrick
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Samuel G. Liss
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Pradip Patiath
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Christopher John Perry
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Sabra R Purtill
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Olumide Soroye
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Kimberly S. Stevenson
Director
|
Grant | 1.3K | - |
| May 19, 2026 | Therese Michele Vaughan
Director
|
Grant | 1.3K | - |
| May 15, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $63.7K |
| Apr 15, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $68.6K |
| Mar 31, 2026 | Gregory S. Hendrick
Director
|
Grant | 138 | - |
| Mar 31, 2026 | Samuel G. Liss
Director
|
Grant | 158 | - |
| Mar 31, 2026 | Christopher John Perry
Director
|
Grant | 138 | - |
| Mar 31, 2026 | Sabra R Purtill
Director
|
Grant | 138 | - |
| Mar 17, 2026 | Elizabeth Mann
Chief Financial Officer
|
Sell | 400 | $81.9K |
| Feb 20, 2026 | Gregory S. Hendrick
Director
|
Buy | 500 | $90.1K |
| Feb 20, 2026 | Christopher John Perry
Director
|
Buy | 1.0K | $180.0K |
| Feb 20, 2026 | Kimberly S. Stevenson
Director
|
Buy | 1.0K | $179.2K |
| Jan 15, 2026 | Kathy Card Beckles
Officer
|
Grant | 7.4K | - |
| Jan 15, 2026 | Sunita Bhatia-Holzer
Officer
|
Grant | 6.1K | - |
| Jan 15, 2026 | Nicholas Daffan
Chief Technology Officer
|
Grant | 8.7K | - |
| Jan 15, 2026 | David J. Grover
Officer
|
Grant | 1.2K | - |
| Jan 15, 2026 | Elizabeth Mann
Chief Financial Officer
|
Grant | 11.0K | - |
| Jan 15, 2026 | Lee M Shavel
Chief Executive Officer
|
Grant | 40.2K | - |
| Dec 31, 2025 | Gregory S. Hendrick
Director
|
Grant | 70 | - |
| Dec 31, 2025 | Samuel G. Liss
Director
|
Grant | 134 | - |
| Dec 31, 2025 | Christopher John Perry
Director
|
Grant | 117 | - |
| Dec 31, 2025 | Sabra R Purtill
Director
|
Grant | 117 | - |
| Dec 16, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $65.9K |
| Nov 18, 2025 | Lee M Shavel
Chief Executive Officer
|
Sell | 2.2K | $480.8K |
| Nov 17, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $65.1K |
| Oct 31, 2025 | Jeffrey J Dailey
Director
|
Buy | 500 | $108.5K |
| Oct 31, 2025 | Gregory S. Hendrick
Director
|
Buy | 500 | $108.1K |
| Oct 31, 2025 | Sabra R Purtill
Director
|
Buy | 450 | $98.1K |
| Oct 15, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $72.7K |
| Sep 30, 2025 | Samuel G. Liss
Director
|
Grant | 119 | - |
| Sep 30, 2025 | Christopher John Perry
Director
|
Grant | 104 | - |
| Sep 16, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $76.4K |
| Sep 3, 2025 | Nicholas Daffan
Chief Technology Officer
|
Sell | 5.4K | $1.4M |
| Sep 3, 2025 | Nicholas Daffan
Chief Technology Officer
|
Option | 4.6K | $488.6K |
| Aug 18, 2025 | Lee M Shavel
Chief Executive Officer
|
Sell | 2.2K | $589.6K |
| Aug 15, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $80.4K |
| Aug 13, 2025 | Christopher John Perry
Director
|
Buy | 1.0K | $259.8K |
| Aug 4, 2025 | Nicholas Daffan
Chief Technology Officer
|
Sell | 5.4K | $1.5M |
| Aug 4, 2025 | Nicholas Daffan
Chief Technology Officer
|
Option | 4.6K | $488.6K |
| Aug 1, 2025 | Lee M Shavel
Chief Executive Officer
|
Grant | 1.8K | - |
| Jul 15, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $91.2K |
| Jul 3, 2025 | Nicholas Daffan
Chief Technology Officer
|
Sell | 5.4K | $1.6M |
| Jul 3, 2025 | Kathy Card Beckles
Officer
|
Sell | 326 | $98.1K |
| Jul 3, 2025 | Nicholas Daffan
Chief Technology Officer
|
Option | 4.6K | $488.5K |
| Jun 30, 2025 | Gregory S. Hendrick
Director
|
Grant | 51 | - |
| Jun 30, 2025 | Samuel G. Liss
Director
|
Grant | 96 | - |
| Jun 30, 2025 | Christopher John Perry
Director
|
Grant | 38 | - |
| Jun 30, 2025 | Sabra R Purtill
Director
|
Grant | 38 | - |
| Jun 17, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $92.7K |
| Jun 13, 2025 | Samuel G. Liss
Director
|
Sell | 11.7K | $3.6M |
| Jun 13, 2025 | Samuel G. Liss
Director
|
Option | 11.7K | $850.3K |
| Jun 5, 2025 | Lee M Shavel
Chief Executive Officer
|
Grant | 44.7K | - |
| Jun 4, 2025 | Nicholas Daffan
Chief Technology Officer
|
Sell | 5.4K | $1.7M |
| Jun 4, 2025 | Nicholas Daffan
Chief Technology Officer
|
Option | 4.6K | $488.5K |
| May 20, 2025 | Jeffrey J Dailey
Director
|
Grant | 735 | - |
| May 20, 2025 | Bruce Edward Hansen
Director
|
Grant | 735 | - |
| May 20, 2025 | Gregory S. Hendrick
Director
|
Grant | 735 | - |
| May 20, 2025 | Kathleen Applegate Hogenson
Director
|
Grant | 735 | - |
| May 20, 2025 | Samuel G. Liss
Director
|
Grant | 735 | - |
| May 20, 2025 | Christopher John Perry
Director
|
Grant | 735 | - |
| May 20, 2025 | Sabra R Purtill
Director
|
Grant | 735 | - |
| May 20, 2025 | Olumide Soroye
Director
|
Grant | 735 | - |
| May 20, 2025 | Kimberly S. Stevenson
Director
|
Grant | 735 | - |
| May 20, 2025 | Therese Michele Vaughan
Director
|
Grant | 735 | - |
| May 16, 2025 | Lee M Shavel
Chief Executive Officer
|
Sell | 2.2K | $671.1K |
| May 15, 2025 | Elizabeth Mann
Chief Financial Officer
|
Sell | 300 | $90.7K |
| May 9, 2025 | David J. Grover
Officer
|
Sell | 5.7K | $1.8M |
| May 9, 2025 | David J. Grover
Officer
|
Option | 5.7K | $457.5K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.